Article
Targeting cancer-specific mutations with RNA-triggered chromatin shredding.
Nature - 1 Aug 2026
Zeng Jingkun, Cheng Zhiyuan, Chen Huadong, Wang Zhaojun, Thompson Jared, Crosby Kadin T, Han Hesong, Singhal Arushi, Ngo Wayne, Xia Chenglong, Rosas-Rivera Daniel, Zhang Zeyuan, Kang Min Hyung, Mao Ying, Diolaiti Morgan E, Lee Giselle C, Diffley John F X, Song Yixuan, Qiu Longhui, Krah Nathan M, Murthy Niren, Jackson Ryan N, Liu Yang, Ashworth Alan, Doudna Jennifer A
Abstract excerpt
Genetic mutations that drive cancer often occur in tumour-suppressor proteins such as the p53 transcription factor, which is altered in 40-50% of cases1,2. However, current therapies often fail to target these mutations because the mutant proteins typically lack defined drug-binding pockets and restoring their endogenous function has proven challenging. Here we program Cas12a2, an RNA-guided CRISPR nuclease with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.